@RNAiAnalyst @A_May_MD Biologically plausible: ~6 wks to manufacture + time to mount a T-cell response, so early relapses happen before the vaccine can act. But a 6-month landmark is post hoc and flatters any delayed-onset therapy. The ITT HR 0.58 is the number that counts. DMFS 0.62 is ok. #ESMO26